Primary Site >> Colorectal Cancer
Gene >> PDCD1
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. PMID: 7706497 |
Ref: TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer. PMID: 21179245 |
Ref: Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. PMID: 22859396 |
Ref: Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. PMID: 23633484 Ref: Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). PMID: 24114613 |
Ref: Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. PMID: 25392179 |
Ref: Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. PMID: 25730880 Ref: Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients. PMID: 25823653 Ref: Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy? PMID: 26140250 Ref: Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. PMID: 26187615 Ref: Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice. PMID: 26452385 Ref: STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. PMID: 26607445 |
Ref: Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. PMID: 26683225 Ref: Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. PMID: 26965581 Ref: Enrichment of Inflammatory IL-17 and TNF-alpha Secreting CD4(+) T Cells within Colorectal Tumors despite the Presence of Elevated CD39(+) T Regulatory Cells and Increased Expression of the Immune Checkpoint Molecule, PD-1. PMID: 27014625 Ref: Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. PMID: 27039171 Ref: Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. PMID: 27070448 Ref: Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. PMID: 27091407 Ref: Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. PMID: 27099521 Ref: Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. PMID: 27339628 Ref: Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. PMID: 27341597 Ref: Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. PMID: 27443512 Ref: Antitumor Effect of Zhihuang Fuzheng Soft Capsules on Tumor-Bearing Mice. PMID: 27493673 Ref: Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. PMID: 27550452 Ref: The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. PMID: 27553906 |
Ref: Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. PMID: 27196573 Ref: Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. PMID: 27813511 Ref: Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. PMID: 28055269 Ref: RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer. PMID: 28057020 Ref: Increased PD-L1 expression in breast and colon cancer stem cells. PMID: 28107571 Ref: PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients. PMID: 28197377 Ref: Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. PMID: 28406723 Ref: Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. PMID: 28459943 Ref: Immunotherapy for Colorectal Cancer. PMID: 28492495 Ref: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. PMID: 28514441 Ref: Intratumoral FoxP3(+)Helios(+) Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer. PMID: 28603527 Ref: Immune Checkpoints as a Target for Colorectal Cancer Treatment. PMID: 28635639 Ref: Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. PMID: 28838649 Ref: PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. PMID: 28932634 Ref: [Immunotherapy of Colorectal and Anal Carcinoma]. PMID: 29239195 Ref: Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology. PMID: 29552640 |
Ref: High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. PMID: 29308317 Ref: Early and Partial Reduction in CD4(+)Foxp3(+) Regulatory T Cells during Colitis-Associated Colon Cancer Induces CD4(+) and CD8(+) T Cell Activation Inhibiting Tumorigenesis. PMID: 29344269 Ref: Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. PMID: 29437869 Ref: Results and challenges of immune checkpoint inhibitors in colorectal cancer. PMID: 29471676 Ref: Genomics and emerging biomarkers for immunotherapy of colorectal cancer. PMID: 29501787 Ref: CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. PMID: 29520442 Ref: CD8(+)CXCR5(+) T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer. PMID: 29544815 Ref: [Association of programmed cell death 1 (PDCD1) gene polymorphisms with colorectal cancer among Han Chinese population]. PMID: 29652996 Ref: Histogram analysis of ADC in rectal cancer: associations with different histopathological findings including expression of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI 67. A preliminary study. PMID: 29719621 Ref: Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer. PMID: 29848685 Ref: RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. PMID: 29872559 Ref: TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. PMID: 29900052 Ref: Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. PMID: 29900061 Ref: (-)-4-O-(4-O-beta-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer. PMID: 30062658 Ref: Upregulation of PDL1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling. PMID: 30066852 Ref: ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer. PMID: 30100393 Ref: Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. PMID: 30151257 Ref: Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II-III colorectal cancer. PMID: 30353144 |